Aldosterone blockade in chronic kidney disease.

Area of Science:

• Nephrology
• Endocrinology
• Cardiovascular Medicine

Background:

• Renin-angiotensin-aldosterone system blockade is standard for chronic kidney disease (CKD).
• Aldosterone's role in CKD progression is gaining attention.
• Mineralocorticoid receptor (MR) antagonists offer a potential therapeutic avenue.

Purpose of the Study:

• To review the efficacy and safety of MR antagonists in CKD.
• To highlight the benefits of MR antagonists beyond current standard therapies.
• To discuss the risk of hyperkalemia and its management.

Main Methods:

• Literature review of studies on MR antagonists in CKD patients.
• Analysis of data on proteinuria, blood pressure, and adverse events.
• Evaluation of risk factors and mitigation strategies for hyperkalemia.

Main Results:

• MR antagonists (spironolactone, eplerenone) reduce proteinuria and blood pressure across CKD stages.
• Hyperkalemia is a significant risk, predictable by renal function.
• Dietary and medication adjustments can mitigate hyperkalemia risk.

Conclusions:

• MR antagonists are promising for managing CKD complications.
• Risk-benefit assessment is crucial for patient selection and management.
• Further research is needed on hard outcomes like ESRD progression and mortality.